Drug intelligence / Profile preview

PPI-461

Development stage: Phase 1
Lead developer: Presidio Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

PPI-461 is a small molecule drug developed by Presidio Pharmaceuticals, Inc. It acts as an inhibitor of the Hepatitis C virus NS5A protein. The drug has shown potent activity against all HCV genotypes and has been evaluated for its safety, tolerability, and antiviral efficacy in clinical trials. PPI-461 exhibits good oral bioavailability and achieves high liver concentrations, which may allow for lower dosing regimens. It is primarily indicated for the treatment of chronic hepatitis C, particularly genotype 1.

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on PPI-461.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPI-461.

Explore the full profile